Bank of Baroda Reviews MCLR; Highlights Changes Across Lending Rate Tenors
Bank of Baroda has reviewed its Marginal Cost of Funds Based Lending Rate (MCLR), which will be effective from August 12, 2026. The review pertains to the lending rate across various tenors, including overnight, one month, three months, six months, and one year.The institution provided details regarding both the existing MCLR rates and the revised rates following the review. Most of the rates remained consistent with their previous listings, with a notable adjustment made for the three-month tenure.
Key details of the MCLR as of August 12, 2026, are presented below:
| MCLR Tenors | Existing Rate (in %) | Revised MCLR (in %) w.e.f. August 12, 2026 |
|---|---|---|
| Overnight | 7.85 | 7.85 |
| One Month | 7.95 | 7.95 |
| Three Month | 8.20 | 8.30 |
| Six Month | 8.50 | 8.50 |
| One Year | 8.75 | 8.75 |
The revision reflects the updated lending parameters, with the three-month MCLR increasing from 8.20% to 8.30%, while all other tenors maintained their previous rate percentages.
BANKBARODA Stock Price Movement
Bank of Baroda shares today slipped by 1.15% to close at ₹247.81, closing well below the day's high of ₹250.98. The stock saw a volume of 6.89 million shares in post-market trading.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.